Studies related to COVID-19 Severity and Vitamin D

"Effect Of Calcifediol Treatment And Best Available Therapy Versus Best Available Therapy On Intensive Care Unit Admission And Mortality Among Patients Hospitalized For COVID-19: A Pilot Randomized Clinical Study"

Effect Decrease
Values #(%) Requiring ICU treatment. Control: 13 (50). Vitamin D: 1 (2)
Trial Design Randomized trial
Trial Length 1-7 Days
Number of Subjects 76
Sex Both Genders
Notes for this study:
In this pilot randomized, open-label, controlled (but not placebo-controlled) trial, 76 patients who had been hospitalized due to COVID-19 took 0.532 mg of calcifediol upon admission (2/3 of participants), and 0.266 mg on both day 3 and 7, (1/3 of participants), or no vitamin D throughout the entire stay. All participants received standard treatment as well.

The main outcomes of interest were the rates of ICU admission and death. Only 2% of the participants who took calcifediol required ICU admission, while 50% of the participants who did not take calcifediol required ICU admission. Two patients who didn’t take calcifediol died, while none who took it died.

Full details on all 4 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.